About the company
Personalis Inc, a leading provider of genomic sequencing and analytics solutions, is revolutionizing the field of cancer immunotherapy with its groundbreaking technologies and innovative products. With a strong focus on personalized medicine, the company is at the forefront of developing next-generation cancer immunotherapies and personalized cancer vaccines. The core offering of Personalis Inc lies in its sequencing and data analysis services, which cater to the growing demand for genomic profiling and personalized treatment plans in the field of oncology. By leveraging cutting-edge sequencing technologies and advanced bioinformatics algorithms, Personalis enables researchers, clinicians, and pharmaceutical companies to gain comprehensive insights into tumor genetics, immune response, and therapeutic targets. One of the flagship products offered by Personalis is ImmunoID NeXT, a comprehensive genomic profiling solution designed specifically for immuno-oncology research. ImmunoID NeXT provides a detailed analysis of both the tumor and the immune system, capturing the complex interplay between cancer cells and the body's immune response. This holistic approach empowers researchers to identify novel biomarkers, predict patient response to various immunotherapies, and ultimately develop personalized treatment strategies. Another groundbreaking product in Personalis' portfolio is NeXT Liquid Biopsy, a non-invasive genomic profiling solution that uses a simple blood sample to detect genetic alterations and monitor tumor dynamics. By analyzing circulating tumor DNA (ctDNA) and other genetic information present in the bloodstream, NeXT Liquid Biopsy allows for real-time monitoring of treatment response, early detection of relapse, and dynamic assessment of tumor heterogeneity. This innovative approach eliminates the need for invasive tissue biopsies and provides a more comprehensive view of tumor genetics. Personalis Inc also offers the NeXT Dx Test, a clinical-grade genomic assay designed for use in diagnosing and monitoring cancer patients. By analyzing genomic alterations in tumor samples, the NeXT Dx Test enables the identification of clinically actionable mutations and helps guide treatment decisions. This test aims to improve patient outcomes by assisting physicians in selecting the most effective therapies and monitoring treatment response over time. In addition to these core products, Personalis provides a range of Pharma Research Solutions that support drug development and clinical trials. These solutions include genomic profiling services for pre-clinical and clinical research, biomarker discovery and validation, and companion diagnostic development. By partnering with pharmaceutical companies, Personalis is actively contributing to the development of targeted therapies and the advancement of precision medicine. Overall, Personalis Inc is a pioneer in the field of genomic sequencing and analytics, empowering researchers, clinicians, and pharmaceutical companies to unlock the full potential of personalized cancer immunotherapy. With its cutting-edge technologies, comprehensive product portfolio, and commitment to advancing precision medicine, Personalis is playing a vital role in shaping the future of cancer treatment.
Website: https://www.personalis.com
Data updated: June 8, 2026
